| Revenue growth | FY26 revenue up 28% YoY to ₹642.3cr. |
|---|---|
| Margins | EBITDA margin compressed to 34.6% due to high RM costs. |
| Order book | 500 MT purchase order from leading Indian player for battery materials. |
| Demand visibility | Healthy demand across verticals; encouraging traction in advanced materials. |
| Management confidence | High; citing strategic milestones and long-term growth trajectory. |
Growth
FY26 Revenue grew 28% YoY to ₹642.3cr; PAT increased 26% to ₹174.3cr. Q4FY26 revenue rose 16% YoY.
Outlook
Commissioning Dahej battery materials plant early CY2027; Phase 1 capacity 25,000 MT. Targeting 100,000 MT by 2030.
Risks
High raw material costs (phosphoric/sulphuric acid), West Asia conflict supply chain disruptions, and gas supply issues.
Earnings Call filed with NSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,170.40
- Market cap
- ₹13,220 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.4×Sector 47.3×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Other Announcement
Sudeep Pharma Limited corrected a clerical error regarding the number of attendees at its Annual General Meeting, updating the count from 45 to 44.
Sudeep Pharma Investor Presentation: Key Takeaways
Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).
Sudeep Pharma Q1 FY27 Results: Net Profit ₹40.6 Cr, Up 29.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹40.6 Cr · +29.7% YoY
Sudeep Pharma Annual General Meeting
Sudeep Pharma Limited held its 37th Annual General Meeting on August 4, 2026. The meeting transacted business including financial statement approval, director appointments, dividend declaration, and ESOP schemes.
Sudeep Pharma Capital Structure Change
Nuvama Crossover Opportunities Funds reduced their stake in Sudeep Pharma Ltd. The promoter field is 'No', indicating a non-promoter equity transaction.